Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
US5447948A · kind A · utility
18Cited by
2References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 7, 1992 |
| Grant date | Sep 5, 1995 |
| Priority date | — |
| Expiry date | May 7, 2012 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/46
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Mazindol and other dopamine and/or noradrenergic reuptake inhibitors are effective to treat negative symptoms in schizophrenia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.